Enzalutamide plus ADT effective in Metastatic Prostate Cancer, Finds study
Written By : Dr. Nandita Mohan
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2021-01-24 18:00 GMT | Update On 2021-01-24 18:00 GMT
Advertisement
Researchers from the Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, North Carolina have recently noted that treatment with enzalutamide plus ADT provides improvements in men with bone and/or lymph node metastases, but may be less effective in men with visceral patterns of spread, according to the study published in the Journal of Urology.
Enzalutamide plus ADT has previously been shown to improve clinical outcomes in men with metastatic hormone sensitive prostate cancer. Hence, Andrew J Armstrong and colleagues conducted this study to assess if and how the pattern of metastatic spread impacts efficacy of enzalutamide plus ADT in men enrolled in ARCHES.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.